文献速递神经介入外周血管DSA

药物涂层球囊治疗症状性颅内动脉狭窄疾病:多中心随机对照试验

Drug-coated Balloon for Endovascular Treatment of Symptomatic Intracranial Stenotic Disease: A Multicenter Randomized Controlled Trial.
PubMed 文献 · Radiology · 2026-01-01

在14家中国三级医院前瞻性随机纳入209例症状性颅内动脉粥样硬化性狭窄(ICAD)伴重度狭窄患者,1:1分配至药物涂层球囊(DCB)组(103例)与裸金属支架(BMS)组(106例)。DCB组6个月造影再狭窄率(11% vs 29%)、6个月症状性再狭窄率(1% vs 10%)及30天至1年复发性缺血事件率(4% vs 13%)均低于BMS组,30天卒中或死亡率两组相似(6% vs 5%)。

要点

  • DCB组6个月造影再狭窄率11%,低于BMS组的29%(RR 0.38,95%CI 0.19–0.78,P=.006)。
  • DCB组6个月症状性再狭窄率1%,低于BMS组的10%(RR 0.13,95%CI 0.02–0.96,P=.02)。
  • 两组30天卒中或死亡率相似(DCB 6% vs BMS 5%;HR 1.24,95%CI 0.38–4.05,P=.73)。

核心结论

  • 在症状性ICAD伴重度狭窄患者中,与BMS置入相比,DCB血管成形术降低了6个月造影再狭窄和症状性再狭窄风险以及30天至1年复发性缺血事件率。

研究设计与样本

  • 多中心前瞻性随机对照试验,14家中国三级医院,209例症状性ICAD伴重度狭窄患者按1:1随机分配至DCB组(103例)和BMS组(106例),在意向治疗人群中分析。

诊断标准与关键数值

  • 主要结局为6个月数字减影血管造影评估的再狭窄,DCB组11% vs BMS组29%(RR 0.38,95%CI 0.19–0.78,P=.006)。
  • 6个月症状性再狭窄率DCB组1% vs BMS组10%(RR 0.13,95%CI 0.02–0.96,P=.02)。
  • 30天至1年复发性缺血事件率DCB组4% vs BMS组13%(HR 0.31,95%CI 0.10–0.94,P=.04)。
  • 30天卒中或死亡率DCB组6% vs BMS组5%(HR 1.24,95%CI 0.38–4.05,P=.73)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Restenosis is a major cause of stroke recurrence after bare-metal stent (BMS) placement in patients with symptomatic intracranial atherosclerotic disease (ICAD). Observational studies have shown that drug-coated balloon (DCB) angioplasty can reduce restenosis rates. Purpose To compare the efficacy and safety of DCB angioplasty with that of BMS placement in individuals with symptomatic ICAD with high-grade stenosis. Materials and Methods Eligible patients with symptomatic ICAD at 14 Chinese tertiary hospitals were prospectively and randomly assigned (1:1 ratio) to the DCB and BMS groups. The primary outcome was 6-month restenosis assessed with digital subtraction angiography. Secondary and safety outcomes included 6-month symptomatic restenosis, 30-day to 1-year recurrent ischemic event, and 30-day stroke or death. Between-group differences in outcomes were tested using generalized linear and Cox regression models. Results Between July 2021 and March 2023, 209 participants (median age, 59 years [IQR, 52-66 years]; 157 men), 103 and 106 in the DCB and BMS groups, respectively, were included in the intention-to-treat analysis. A total of 164 participants completed the 6-month digital subtraction angiography follow-up, and 203 participants completed the 1-year clinical follow-up. The 6-month angiographic restenosis rate was lower in the DCB group than in the BMS group (11% vs 29%; risk ratio, 0.38 [95% CI: 0.19, 0.78]; P = .006). The DCB group also had a lower 6-month symptomatic restenosis rate (1% vs 10%; risk ratio, 0.13 [95% CI: 0.02, 0.96]; P = .02) and lower 30-day to 1-year recurrent ischemic event rate (4% vs 13%; hazard ratio, 0.31 [95% CI: 0.10, 0.94]; P = .04). The 30-day stroke or death rate was similar in the DCB and BMS groups (6% vs 5%; hazard ratio, 1.24 [95% CI: 0.38, 4.05]; P = .73). Conclusion In individuals with symptomatic ICAD with high-grade stenosis, DCB angioplasty reduced the 6-month risks of angiographic restenosis and symptomatic restenosis and 30-day to 1-year recurrent ischemic event rate compared with BMS placement. Chinese Clinical Trial Registry no. ChiCTR2100046829 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Wojak in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Guan S, Tong X, Li X, et al. Drug-coated Balloon for Endovascular Treatment of Symptomatic Intracranial Stenotic Disease: A Multicenter Randomized Controlled Trial. Radiology. 2026. PMID: 41557900. doi:10.1148/radiol.250893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。